drugset / Trial / NCT04836260
Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19
Phase 3
Unknown
100 enrolled
University Hospital, Geneva
Hôpital Fribourgeois · collabOspedale Regionale di Lugano · collabUniversity Hospital, Basel, Switzerland · collab
Non-randomizedSingle-groupOpen-labelPrevention
Summary
Convalescent plasma therapy has been recognized as safe and plasma transfusion is routinely used in clinical practice. A recent study showed that early administration of convalescent plasma can decrease the risk of complications in specific high-risk population. The aim of the present study is to offer convalescent plasma therapy to immunocompromised patients and older adults in the early phase of a SARS-Cov-2 infection in order to accelerate viral clearance and prevent complication
Timeline
- Start
- 2021-04-08
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SARS-CoV-2 convalescent plasma | Protein / enzyme biologic | — | — |